Working Group 5-Pathophysiological roles of ALDO/MR in novel target tissues
Key outcomes will be to characterize the novel roles for aldosterone and MR activation in these non-classical tissue targets as well as to identify potentially new therapeutic indications prone to MR antagonism.
A new exciting area of MR biology began with the identification of MR expression in different target tissues, such as lung airway epithelia , eyes and skin, brain, cardiomyocytes, vasculature, macrophages/monocytes, erythrocytes and adipose tissue. This particular distribution of MR in such a wide range of tissues has suggested novel and unexpected roles for MR under different physiological and pathophysiological contexts, ranging from metabolic syndrome and oxidative stress to choroid retinopathy and stress adaptability.
The goal of WG5 is to gain deeper insights in the pathophysiological roles of MR activation in “non classical” targets of aldosterone, focusing particularly on adipose tissue, brain, eye (choroid vessels) and blood cells (leukocytes and erythrocytes). WP5 has 3 main aims:
- Understand the pathophysiological role of aldosterone and MR in ‘non-classical targets” and their potential implications in disease states. Interactions with the other WGs will be essential to achieve this goal since an integrated approach will be required. For example, consequences of hyperaldosteronism on these targets, interactions between these novel targets and the cardiovascular or renal systems or the role of the microvasculature will be important to be analyzed.
- Identify new signaling pathways of MR in novel target tissues, taking advantage of different
- expertise and animal models available in the COST network, which should accelerate scientific progress in each research group.
- Facilitating the exchange of researchers (senior scientists and students) to promote the sharing of different expertise in different scientific areas, from neuroscience, metabolism, fish biology, oxidative stress and inflammation. This should help the acquisition of diverse scientific approaches, potentially revealing novel unexpected applications in each research settings.
- Propose novel potential applications of MR antagonists in diverse clinical settings, where the use of MR blockers or modulators has not yet been explored. This will favor translational and clinical studies in WG6
Working Group 5 members
Massimiliano Caprio, WG Leader, Italy
Decio Armanini, Italy
Francine-Behar Cohen, France
Ron de Kloet, The Netherlands
Patrick Prunet, France
Francesco Fallo, Italy
Pernille B. Lærkegaard Hansen, Denmark
Nourdine Faresse, Switzerland
Research Group 1
Keywords: Mineralocorticoid receptor,adipose tissue, vascular endothelium, Intercellular Adhesion Molecule 1 (ICAM-1)
Research Group 2
Keywords: Stress-related brain disorders, corticosteroid hormone, adrenal
Research Group 3
Head: Pernille Bjørg Lærkegaard Hansen, PhD, MSc, Professor, Cardiovascular and Renal Research
Institute for Medical BiologyJ.B. Winsløws Vej 21, 3. sal , 5000 Odense C, Denmark
Phone: +45 65503717
Fax: +45 6613 3479
Homepage: Pernille B. Lærkegaard Hansen
- Aldosterone, vascular and renal effects studied in human tissue and transgenic mice.
- Role of non-L-type calcium channels for blood pressure regulation and kidney function studied in human and mice
Research Group 4
Keywords: Adrenal steroid production, primary aldosteronism, aldosterone and MR activation in adipose tissue
Research Group 5
Head: Paloma Pérez, Dept. of Pathology and Cell and Molecular Therapy, Instituto de Biomedicina de Valencia (IBV-CSIC), Spain
Keywords: Glucocorticoid receptor, Mineralocorticoid receptor, cutaneous biology, inflammation
Research Group 6
Head: Ozlen Konu, Associate Professor, Bilkent University, Department of Molecular Biology and Genetics, 06800 Ankara Turkey
Keywords: RNAi/overexpression of receptors, nicotine, aldosterone, estrogen and anticancer drugs.